You are right. However, the problem for Atomo is that it has not demonstrated its ability to sell its devices overseas, at least not consistently. The NG biotech was one-off, the Access bio US deal is likely to be paid rather than taken, the HIV deal we signed was low on margin...
This gives me concerns about whether AT1 could sign any significant deals in the near term, if not, what we have is only potential
